ZA966954B - Anti-selectin antibodies for prevention of multiple organ failure after polytrauma and for prevention of acute organ damage after extracorporeal blood circulation. - Google Patents

Anti-selectin antibodies for prevention of multiple organ failure after polytrauma and for prevention of acute organ damage after extracorporeal blood circulation.

Info

Publication number
ZA966954B
ZA966954B ZA9606954A ZA966954A ZA966954B ZA 966954 B ZA966954 B ZA 966954B ZA 9606954 A ZA9606954 A ZA 9606954A ZA 966954 A ZA966954 A ZA 966954A ZA 966954 B ZA966954 B ZA 966954B
Authority
ZA
South Africa
Prior art keywords
prevention
polytrauma
blood circulation
extracorporeal blood
selectin antibodies
Prior art date
Application number
ZA9606954A
Other languages
English (en)
Original Assignee
Protein Designs Labs Inc
Boehringer Mannheim Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protein Designs Labs Inc, Boehringer Mannheim Gmbh filed Critical Protein Designs Labs Inc
Publication of ZA966954B publication Critical patent/ZA966954B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C07K16/2854—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • External Artificial Organs (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA9606954A 1995-08-17 1996-08-16 Anti-selectin antibodies for prevention of multiple organ failure after polytrauma and for prevention of acute organ damage after extracorporeal blood circulation. ZA966954B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP95112895 1995-08-17
EP95114696 1995-09-19
US57895395A 1995-12-27 1995-12-27

Publications (1)

Publication Number Publication Date
ZA966954B true ZA966954B (en) 1998-02-16

Family

ID=27236574

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9606954A ZA966954B (en) 1995-08-17 1996-08-16 Anti-selectin antibodies for prevention of multiple organ failure after polytrauma and for prevention of acute organ damage after extracorporeal blood circulation.

Country Status (11)

Country Link
EP (1) EP0868197B1 (cs)
JP (1) JP3604699B2 (cs)
AT (1) ATE265861T1 (cs)
AU (1) AU6773596A (cs)
CA (1) CA2229140A1 (cs)
CZ (1) CZ45498A3 (cs)
DE (1) DE69632407T2 (cs)
HU (1) HUP9901673A3 (cs)
PL (1) PL187090B1 (cs)
WO (1) WO1997006822A1 (cs)
ZA (1) ZA966954B (cs)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6172213B1 (en) 1997-07-02 2001-01-09 Genentech, Inc. Anti-IgE antibodies and method of improving polypeptides
US5994511A (en) 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
GB9919713D0 (en) 1999-08-19 1999-10-20 Queen Mary & Westfield College New medical use of high density lipoprotein
ES2389037T3 (es) 2002-03-13 2012-10-22 Biogen Idec Ma Inc. Anticuerpos anti-alpha V beta 6
CN104072614B (zh) * 2005-07-08 2017-04-26 生物基因Ma公司 抗-αvβ6 抗体及其用途
CA2662905A1 (en) 2006-07-10 2008-01-17 Biogen Idec Ma Inc. Compositions and methods for inhibiting growth of smad4-deficient cancers
WO2014144466A1 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anti-alpha v beta 6 antibodies and uses thereof
WO2014143739A2 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anti-alpha v beta 6 antibodies and uses thereof
US20220249814A1 (en) 2018-11-19 2022-08-11 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
EP4309722A3 (en) 2019-12-13 2024-08-07 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69232780T2 (de) * 1991-06-25 2003-01-30 Dana-Farber Cancer Institute, Boston Monoklonaler antikörper gegen lymphozytenassoziiertes zelloberflächenprotein
AU2410292A (en) * 1991-07-29 1993-03-02 Dana-Farber Cancer Institute, Inc. Monoclonal antibodies to leukocyte adhesion molecule-1
KR100371784B1 (ko) * 1992-12-01 2003-07-22 프로테인 디자인랩스, 인코포레이티드 L-셀렉틴과반응성인인체화된항체
AU2185195A (en) * 1993-11-30 1995-06-19 Protein Design Labs, Inc. Reperfusion therapy using antibodies to L-selectin

Also Published As

Publication number Publication date
HUP9901673A3 (en) 2001-06-28
PL325012A1 (en) 1998-07-06
ATE265861T1 (de) 2004-05-15
PL187090B1 (pl) 2004-05-31
DE69632407T2 (de) 2005-06-02
JP3604699B2 (ja) 2004-12-22
EP0868197B1 (en) 2004-05-06
AU6773596A (en) 1997-03-12
CA2229140A1 (en) 1997-02-27
CZ45498A3 (cs) 1999-01-13
EP0868197A4 (cs) 1998-11-18
EP0868197A1 (en) 1998-10-07
DE69632407D1 (de) 2004-06-09
WO1997006822A1 (en) 1997-02-27
HUP9901673A2 (hu) 1999-08-30
JPH10510553A (ja) 1998-10-13

Similar Documents

Publication Publication Date Title
AR004357A1 (es) Compuestos de 1-fenil-2-dimetilaminometil-ciclohexan-1-ol, y procedimiento de preparacion para dichos compuestos.
AU594488B2 (en) Agents for the treatment of arthroses
AU3070897A (en) Global financial services integration system and process
CA2265464A1 (en) Therapy for .alpha.-galactosidase a deficiency
AU4902096A (en) System and method for providing end-user free email
WO1998025597A3 (en) Method for treating and preventing heart failure and ventricular dilatation
EP0652512A3 (en) Method and system for managing component connections.
EP0487627A4 (en) Wound healing preparations containing heparanase
NO890793D0 (no) Fremgangsmaate og installasjon for behandling av vann.
TR199501643A2 (tr) Yünün enzimlerle tedavisi icin yöntem.
NO975557L (no) Immortalisering og dissimortalisering av celler
ZA966954B (en) Anti-selectin antibodies for prevention of multiple organ failure after polytrauma and for prevention of acute organ damage after extracorporeal blood circulation.
AU7150294A (en) Method and system of collecting, processing and storing blood components
AU7816694A (en) Method and system for the treatment of seeds and bulbs
DE69523296D1 (de) Molkeprotein/polysaccharide Gel, hergestellt durch Hochdruckbehandlung
EP0663218A3 (en) Method and system of cardiac stimulation in VDD (R) mode.
GR3021215T3 (en) Transport of solutions of cellulose through pipes.
EP0858262A4 (en) THROMBIN INHIBITORS
AU4977896A (en) Immunotherapy screening, prognosis, and treatment methods and compositions
NO974811D0 (no) CNS-utvekstmodulatorer, preparater, celler og fremgangsmåter som omfatter og anvender slike
AU3166295A (en) Imidazopyridine-azolidinones
AU3439799A (en) Immunization against and treatment for infection by (h.pylori)
NO881414D0 (no) Fremgangsmaate for behandling av spillvann og annet urent vann.
FI841988A7 (fi) Immunosuppressiivista tekijää tuottava mutantti, humaani T-solulinja sekä menetelmä sellaisten mutanttien tuottamiseksi.
PL319024A1 (en) 4-thia-1-azabicyclo(3.2.0) heptane-3-imino-2-isopropylideno-7-ketoanalgones of beta-lactames, method of obtaining them and their application